Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160

HCP Portal Login
a

Notification Regarding Revision of Consolidated Financial Forecasts (IFRS) for the Fiscal Year Ended March 31, 2023

For Print(PDF)

Listed Company Name: Eisai Co., Ltd.
Representative: Haruo Naito
Representative Corporate Officer and CEO
Securities Code: 4523
Stock Exchange Listings: Prime Market of the Tokyo Stock Exchange

Inquiries: Sayoko Sasaki
Vice President
Corporate Communications
Phone +81-3-3817-5120

 

Eisai Co., Ltd. (“the Company”) announced today that based on trends in business results, etc., the Company has revised its consolidated financial forecasts for the fiscal year ending March 31, 2023 (April 1, 2022 to March 31, 2023) previously announced on November 7, 2022, as follows.

 

1. Revised consolidated financial forecasts for the fiscal year ending March 31, 2023 (April 1, 2022 to March 31, 2023)

(Unit: Millions of yen, unless otherwise noted.)

Revenue Operating
profit		 Profit before
income taxes		 Profit for
the year		 Profit attributable to owners of the parent Basic
earnings
per share
Previously announced forecast (A)
(November 7, 2022)		 760,000 55,000 56,500 58,000 57,000 197.80 yen
Currently revised forecast (B) 744,000 40,000 45,000 56,500 55,000 193.30 yen
Change in amount (B – A) (16,000) (15,000) (11,500) (1,500) (2,000)
Percentage of change (%) (2.1%) (27.3%) (20.4%) (2.6%) (3.5%)
(Reference) Business results for the fiscal year ended  March 31, 2022 756,226 53,750 54,458 45,717 47,954 167.27 yen

 

2. Reason for revision of the consolidated financial forecasts
Based on trends in foreign exchange and product sales, revenue is expected to be ¥744.0 billion, a decrease of ¥16.0 billion from the previous forecast (of which approximately ¥9.5 billion is due to foreign exchange fluctuations).

Due to the decrease in gross profit resulting from the decline in revenue (a decrease of approximately ¥9.5 billion from the previous forecast) and the increase in R&D expenses (an increase of ¥6.5 billion from the previous forecast) resulting from aggressive investments with the good progress of clinical trials for Alzheimer’s disease treatment lecanemab and the review of existing development projects, operating profit is expected to be ¥40.0 billion, a decrease of ¥15.0 billion from the previous forecast.
As a result of the decrease in operating profit and other factors, tax expenses are expected to decrease ¥10.0 billion from the previous forecast, profit for the year is expected to be ¥56.5 billion, a decrease of ¥1.5 billion from the previous forecast, and profit attributable to owners of the parent is expected to be ¥55.0 billion, a decrease of ¥2.0 billion from the previous forecast.

The annual dividend forecast remains unchanged at ¥160 per share, with the year-end dividend of \80 per share (same amount as the previous period) together with the interim dividend (end of the second quarter) of \80 per share, as previously forecast.

* Please note that actual business results may change due to several factors since the above-mentioned forecasts were made based on information available as of May 9, 2023.

Our Values

Values are an integral part of our foundation. With every decision, we ensure that we follow:

Integrity

Integrity is the living up to legal, moral and ethical principles in the conduct of HI-Eisai Pharmaceutical Inc. business. It means that each employee embodies the value of integrity, and therefore represents the company in honesty and rectitude in all the ways they do their work.

It is expected that each employee would make decisions guided by good judgement, not just for one‘s self, but for HI-Eisai as the company. An employee who acts with integrity ensures that he has understanding of the principles by which the company operates, and in situations where he lacks clarity, will actively seek guidance.

Respect

The company is committed to ensure that it maintains a safe, inclusive, and healthy working environment that promotes productivity among employees. All employees are expected to show respect to fellow employees, customers, and patients, regardless of differences in gender, culture, backgrounds, and beliefs. Leaders in the organization are likewise expected to promote inclusivity with their teams, and shall not tolerate any discriminatory and offensive actions.

Accountability

Accountability at work means assuming responsibility for the business outcome and how that is achieved. It means that every employee, in whichever position, are equally responsible for the decisions and actions they make for the company. It is likewise, the responsibility of each employee to report, any knowledge of misconduct or potential violation to the company‘s rules and regulations.

Patient-Centric

At the heart of the company‘s operation are the patients. This means that every decision to be made, considers the potential impact and benefit to the patients. As such, the company commits itself in ensuring that business objectives align with its principle of human health care or hhc. The programs created and implemented are based on how well they could contribute to improving patients‘ lives.

For field-based employees, being patient-centric means that the focus of engagements with customers are on understanding patient needs as well as providing these stakeholders with comprehensive information on how HI-Eisai‘s products can support their patients goals.

For each employee, being patient-centric means taking on their responsibilities with care and consideration on how it impacts the patients experience, be it by making relevant information readily available for the doctors; or by ensuring access and availability to the medicines we offer.

Excellence

As a patient-centric company, we define Excellence by the outstanding quality of our work to improve patients‘ lives. Each employee is expected to consistently demonstrate work ethics that align to our values, policies, and our desire to provide above standard service. The company is committed in ensuring that all actions are in compliance with legal requirements.

Being excellent means that every employee passionately strives to be better and participates in the company‘s initiatives to develop their members in terms of knowledge, skills, and behavior, which will support a continuously improving, responsible and performance-driven workforce.

Our Vision

To be a successful and sustainable business in the Philippines by driving innovation and providing solutions to address unmet healthcare needs fueled by high-performing employees who deliver meaningful value and experience to patients and their families.

Our Mission

We give first thought to patients and their families, and to increasing the benefits health care provides.

Unit 2, 22nd Floor, Tower 6789, 6789 Ayala Avenue, Makati City

+63 28887 5160